Story perspectives

Eli Lilly’s retatrutide delivers 20.8% weight loss

By Drooid · Oct 1, 2026, 3:57 PM UTC · How we work

Summary

Eli Lilly Announces Weight-Loss

Eli Lilly announced that retatrutide achieved up to 20.8% weight loss in a phase 3 trial.
The 12 mg dose produced an average loss of 49.6 lb (20.8%) over 80 weeks.
More than half of participants on 12 mg fell below the obesity BMI threshold.
A1C dropped up to 1.6 points, with 40% of users reaching below 5.7%.
Lilly plans to file a Biologics License Application in early 2027 to secure 12-year FDA exclusivity.

Summary

Eli Lilly Breaks Ground

Eli Lilly broke ground on its new manufacturing campus in Generation Park, Houston, Texas on Sept. 21, 2026.
The Phase 3 trial will test a co-formulation delivering both agents in one injection to improve adherence.
Analysts say the combo could challenge Novo Nordisk’s amylin-GLP-1 drug CagriSema, expected early next year.
Chief Scientific Officer Dan Skovronsky called eloralintide the first amylin-specific agonist, not a calcitonin-targeting drug.

1 of 2

Eli Lilly Announces Weight-Loss

Eli Lilly announced that retatrutide achieved up to 20.8% weight loss in a phase 3 trial.
The 12 mg dose produced an average loss of 49.6 lb (20.8%) over 80 weeks.
More than half of participants on 12 mg fell below the obesity BMI threshold.
A1C dropped up to 1.6 points, with 40% of users reaching below 5.7%.
Lilly plans to file a Biologics License Application in early 2027 to secure 12-year FDA exclusivity.

1 / 2